Cargando…
Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1
BACKGROUND: Pembrolizumab is the recommended first‐line therapy for patients with advanced non‐small‐cell lung cancer (NSCLC) and a programmed death ligand‐1 (PD‐L1) tumor proportion score (TPS) of ≥50% without driver mutations. However, its efficacy and safety for patients ≥75 years have not been p...
Autores principales: | Masuda, Takeshi, Fujitaka, Kazunori, Suzuki, Tomoko, Hamai, Kosuke, Matsumoto, Naoko, Matsumura, Mirai, Isoyama, Shoko, Ueno, Sayaka, Mito, Mineyo, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Kawano, Reo, Masuda, Ken, Nishino, Ryohei, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Hattori, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161325/ https://www.ncbi.nlm.nih.gov/pubmed/35488720 http://dx.doi.org/10.1111/1759-7714.14428 |
Ejemplares similares
-
Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study
por: Isoyama, Shoko, et al.
Publicado: (2022) -
First‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report
por: Hamai, Kosuke, et al.
Publicado: (2020) -
Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2020) -
Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
por: Watari, Naokazu, et al.
Publicado: (2022) -
Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis
por: Horimasu, Yasushi, et al.
Publicado: (2021)